Aspire Biopharma Holdings, Inc. 8-K

What Happened
Aspire Biopharma Holdings, Inc. filed a Certificate of Amendment with the Delaware Secretary of State on May 11, 2026 to implement a 1-for-30 reverse stock split of its issued and outstanding common stock. Under the amendment, every thirty (30) existing shares will be combined into one (1) new share; the reverse split becomes effective as of the effective time set forth in the Certificate. The company’s trading symbol will remain "ABSP" and the new CUSIP for the common stock after the split is 738920305.

Key Details

• Reverse split ratio: 1-for-30 (30 old shares → 1 new share).
• Certificate of Amendment filed with Delaware on May 11, 2026; reported on Form 8-K.
• No fractional shares will be issued; any fractional shares resulting from the split will be rounded up to the nearest whole share.
• Trading symbol unchanged ("ABSP"); new CUSIP: 738920305.

Why It Matters
A reverse stock split reduces the number of outstanding shares and proportionally increases the per‑share price (mathematically 1/30th as many shares outstanding after the split). This can affect share liquidity, the way your holdings appear in brokerage accounts, and administrative identifiers (new CUSIP). Investors should check brokerage statements after the effective date to confirm updated share counts and note that the company kept its trading symbol the same.